6CM
COYA icon

683 Capital Management’s Coya Therapeutics COYA Stock Holding History

683 Capital Management’s Portfolio COYA Stock Details COYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$276K Sell
70,000
-10,128
-13% -$47.4K 0.01% 209
2025
Q4 		$465K Buy
+80,128
New +$487K 0.02% 198

Other funds holding COYA

DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PMG
Private Management Group Irvine, California $3.47B AUM 13.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

683 Capital Management's COYA Position: Q1 2026 in Review

683 Capital Management reduced its Coya Therapeutics (COYA) stake by 13% in Q1 2026, selling an estimated $47.4K and leaving 70,000 shares worth $276K. The position accounts for 0.01% of the portfolio, ranked #209.

683 Capital Management first reported a position in COYA in Q4 2025 and has held it in 2 quarters since. The position peaked at $465K in Q4 2025. 56 funds tracked by Wall St. Rank hold COYA as of Q1 2026.

  • 683 Capital Management held 70,000 shares of Coya Therapeutics worth $276K as of Q1 2026.
  • 683 Capital Management sold 10,128 Coya Therapeutics shares in Q1 2026, an estimated $47.4K.
  • Coya Therapeutics made up 0.01% of 683 Capital Management's portfolio in Q1 2026, its #209 holding.
  • 683 Capital Management first reported a position in Coya Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 683 Capital Management's Coya Therapeutics position peaked at $465K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Coya Therapeutics as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.